Kevin Thornal joined Hologic in August 2014 as Vice President, Customer Experience, Field Service and Clinical Applications for the Breast and Skeletal Health division. He transitioned to Vice President, Breast & Skeletal Health for the Europe, Middle East and Africa region in early 2016, and was promoted to President of our Cynosure division in July 2017. He has now taken on the role of President for the Diagnostics division as of July 2019.
Prior to joining Hologic, Kevin worked at Stryker from 2004 to 2014 in positions of increasing responsibility in sales, marketing, and mergers and acquisitions. Throughout his career, Kevin has established a track record of leading businesses that deliver strong growth and commercial excellence. Before joining the medical technology industry, Kevin played professional football, including a short stint with the Atlanta Falcons. He holds a Bachelor of Arts degree in History and minors in English and Secondary Education from Southern Methodist University.
Dr. Miriam Bloch is an accomplished physician with over 25 years of experience in pathology, laboratory medicine, laboratory directorship and pharmaceutical product development. She has board certification in Anatomic and Clinical Pathology and Cytopathology. She has worked with numerous companies, including Epic Sciences, Ignyta, PPD, Immunovative Therapies and Neogenomics. Miriam is a graduate of the University of Pennsylvania and did her medical training at the University of Kansas and the Hospital of the University of Pennsylvania.
Debra Hadley has had a distinguished career and broad experiences in both large and small laboratories. She was most recently at Genoptix as Vice President of Operations Excellence and Head of Laboratory Operations and formerly held roles with GE Healthcare Life Sciences, Clarient, Genzyme Genetics, US Labs and Quest Diagnostics and the Nichols Institute. She graduated from Pepperdine University with a Bachelor's Degree in Biology and is a licensed Clinical Laboratory Scientist in the State of California. Deb also has an MBA in Technology Management, and a Lean Six Sigma Black Belt Certification.
Karla Kelly has more than 30 years of experience as a business and healthcare lawyer, with deep experience in the life sciences industry. Her legal career includes serving as an associate, special counsel and partner at local law firms and partnerships, including Gray Cary Ames & Frye (now DLA Piper) and Luce Forward (now Dentons US LLP), assistant general counsel at Scripps Health, and as general counsel for other private and public companies. Karla has expertise in in the areas of regulatory, general business and corporate law with a focus on FDA regulation of medical devices and clinical laboratory developed tests (LDT's); clinical research, corporate compliance and governance, including federal and state fraud and abuse issues, healthcare regulatory matters, provider and patient relations and board of directors governance. Karla also has significant experience in complex business transactions, including joint ventures, mergers, acquisitions, and IPO's. As general counsel, Karla oversees risk management, litigation, intellectual property protection, securities transactions; contractual relationships, and legal compliance of corporate operations in the context of business, corporate and healthcare law. Representative clients in the past include hospitals, managed care health plans, integrated healthcare systems, medical device companies, health information exchange organizations; community clinics, physician practices, clinical research organizations, CLIA and CAP certified clinical laboratories, biotech companies, academic institutions and non-profit community-based organizations. Karla obtained her law degree in 1984 from George Washington University School of Law, and prior to that, practiced as a registered nurse in obstetrics in the private sector and with the US Navy Nurse Corps after receiving a bachelor's degree in nursing from the College of St. Catherine.
Debbie has spent the past 20 years successfully securing medical policy coverage and reimbursement for diagnostics and medical devices in start-ups and Fortune 500 companies including Cytyc/Hologic, Natera, Liposcience, Gambro and Johnson & Johnson Medical, Inc. She has held multiple Executive Leadership roles building and directing successful Market Access teams responsible for coding, coverage, contracting and reimbursement within Commercial and Governmental health plans. Debbie is an active coalition member within the Coalition for 21st Century Medicine (C21), the American Clinical Laboratory Association (ACLA) and the California Clinical Laboratory Association (CCLA) sitting on various billing, reimbursement and public policy workgroups/committees within these organizations. Debbie holds a Bachelor’s degree from the University of Memphis and resides in Charlotte, NC.
Matt Sargent has more than 20 years of life science experience, with a strong focus in the commercialization of molecular diagnostic testing services. Matt has served as the Vice President of Sales at Biotheranostics since 2013, during which time he has played a critical role in the commercial growth and development of the organization. Prior to Biotheranostics he was Vice President of Oncology Sales for Caris Life Sciences, where he built and launched the oncology team resulting in significant sales growth and market penetration of their NGS-based molecular profiling platform. He has also held senior sales leadership positions in molecular diagnostics at MedTrust Online and Exiqon Diagnostics. Matt received a bachelor's degree in anatomy and animal physiology from Cornell University, a master's degree in cancer physiology from the State University of New York at Buffalo, and a master's degree in business administration from Pepperdine University.
Lisa Whitmyer has over 19 year’s experience as a sales and marketing leader, successfully launching products in the areas of diagnostics and medical/surgical devices for start-up and Fortune 500 companies, including Cytyc/Hologic, Precision Therapeutics and Thermedx prior to joining Biotheranostics in 2013. Lisa also has held multiple sales and marketing leadership roles where she built teams that established standard of care in their respective markets. She holds a bachelor’s degree from Wittenberg University.
Dr. Catherine Schnabel has over 15 years of experience as an industry scientist across pharmaceutical, clinical and diagnostics research, including positions with Genentech, Genoptix, and Amylin Pharmaceuticals. Joining Biotheranostics in 2009, she has led the translational science and strategic programs for clinical development of proprietary molecular diagnostics in oncology and genomic medicine. Schnabel received her Ph.D. in molecular and cellular biology at the Center for Advanced Biotechnology and Medicine, and was a postdoctoral fellow of the NIH and the Leukemia and Lymphoma Society at Stanford University. Schnabel is an industry leader in the development of evidence-based diagnostics and in building clinical value for molecular tests. She is a named co-inventor on several patents and has authored numerous publications. As Chief Scientific Officer, Dr. Schnabel provides scientific leadership and continued oversight of clinical development, medical strategy, and regulatory plans for Biotheranostics products.
Gail Sloan has over 20 years of financial experience at publicly traded (NASDAQ) companies in the life sciences industry, as well as 8 years with a Big 4 accounting firm. Prior to joining Biotheranostics, Sloan held the Chief Financial Officer and VP Finance positions at La Jolla Pharmaceutical Co. (LJPC), a publicly traded biopharmaceutical company. During her 16-year tenure at LJPC, she played a key role in raising more than $330 million through multiple private placements and public offerings and was responsible for all finance activities, including SEC reporting and compliance with Sarbanes-Oxley Act requirements. Previously, Sloan was Assistant Controller at Affymax Research Institute (AFFY), a publicly traded drug discovery technology company, prior to its acquisition by Glaxo Wellcome in 1995. While at AFFY, Sloan helped lead the spin-out of Affymetrix Inc. (AFFX), a manufacturer of DNA microarrays. Sloan started her finance career at the public accounting firm of Ernst & Young, LLP, where she attained the position of Audit Manager. Sloan is a certified public accountant with the State of California and earned her B.S. in business from California Polytechnic State University, San Luis Obispo.
Bill Zondler has more than 25 years in Information Technology including over 20 years of experience in clinical laboratories, pharmaceutical, medical device, life sciences and biotech industries with both public and private companies. Prior to joining Biotheranostics, Zondler was a full-time Consulting CIO at Axovant Sciences, Inc. a clinical-stage pharmaceutical company in New York. Previously, Zondler was CIO/CTO at Millennium Health, LLC, a privately held healthcare solutions company and clinical laboratory offering Genetics/Pharmacogenetics (PGT) and Toxicology (UDT) testing services. As part of the broader executive team, he was instrumental in leading sweeping changes to improve business processes, systems and improve the customer's user experience in engaging with the company to do business. Prior to Millennium Health, Zondler was Vice President, Information Services and CIO at Prometheus Laboratories, Inc., where he led the integration of the acquisition by NestlÃ© Health Science. Prior to Prometheus, Zondler served as the Vice President, Information Technologies and Facilities at Sanford Burnham Prebys Medical Discovery Institute directing all strategy and operations for IT and Facilities in La Jolla, Calif. and Orlando, Fl. Zondler is a member of the San Diego chapter of the Society for Information Management. In May 2017 Zondler was recognized as a Top Tech Exec Honoree by Top Exec Awards San Diego and the San Diego Business Journal.